Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders

Br J Haematol. 1996 May;93(2):341-4. doi: 10.1046/j.1365-2141.1996.4871026.x.

Abstract

We report on long-term treatment (13-62 months) with cyclosporin A (CyA) in eight patients with autoimmune haematological disorders, resistant to all usual therapies. Three patients had an autoimmune haemolytic anaemia (AHA); four an idiopathic thrombocytopenic purpura (ITP), and one an Evans syndrome. All patients were responsive: six achieved complete remission and two partial remission. The side-effects were moderate and transient. The majority of surviving patients remain dependent on continued drug administration. The CyA appears to be recommendable as a salvage treatment in life-threatening, resistant autoimmune haematological diseases.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Cyclosporine / adverse effects
  • Cyclosporine / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Middle Aged
  • Purpura, Thrombotic Thrombocytopenic / drug therapy*
  • Salvage Therapy
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Cyclosporine